Leukocyte gene expression in post-thrombotic syndrome

Iding, Aaron F.J.; Witten, Anika; Isaacs, Aaron; Castoldi, Elisabetta; Cate, Hugo Ten; Stoll, Monika; Cate‐Hoek, Arina J. ten

doi:10.1016/j.thromres.2021.03.007

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 In a comparative analysis of the transcriptome of leukocytes from patients with thrombosis with and without post-thrombotic syndrome, a difference in gene expression was found and sequenced in 12 different genes, messenger RNA and non-coding RNAs. 22 Different biomarkers, based on endothelial dysfunction, increased in ammatory activity, dysfunction in the coagulation cascade were tested and found differences in serum dosages of CRP, ICAM-1, and Eselectin that were increased in patients with post-thrombotic syndrome while MMP9 and MCP-1 were decreased. 23 We hypothesized that an increase in MPO gene expression may also contribute to PTS sequelae owing to the presence of thrombus remnants, thereby causing a possible capture of NETs consistently over time; however, we cannot verify this hypothesis with our results.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of expression of genes associated with post-thrombotic syndrome

Barros,

Herenio,

Maximiano

et al. 2023

Preprint

View full text Add to dashboard Cite

The prediction of post-thrombotic syndrome (PTS) development among patients with deep venous thrombosis (DVT) is currently based on clinical characteristics alone; reliable biomarkers are unavailable. In this study, the expression of myeloperoxidase (MPO), Fms-related tyrosine kinase 4 (FLT4), and coagulation Factor XIII A chain (F13A1) was evaluated to identify novel biomarkers of PTS. F13A1 of the clotting cascade stabilizes the thrombus; MPO interacts with the endothelium; and FLT4 encodes a vascular endothelium-derived growth factor receptor that participates in angiogenesis. This study evaluated nine patients stratified into three different groups. The control group included three healthy patients; the second group included three patients with DVT without PTS (group II); and the third group included three patients with PTS (group III). The expression of MPO, FLT4, and F13A1 was evaluated in the three groups. A significant decrease in FLT4 expression (ΔCt -2.71; gene expression 0.03, p=0.11 in group II; ΔCt -2.44; gene expression 0.01, p=0.05 in group III) and a non-significant difference in MPO gene expression were found among the three groups; however, there was a notable progressive increase in F13A1 expression (ΔCt 6.54; gene expression 3.5, p=0.02). Despite the low sampling rate in the present study, the decreased FLT4expression and increased of F13A1 expression may represent biomarkers of PTS.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of expression of genes associated with post-thrombotic syndrome

Barros,

Herenio,

Maximiano

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Also, an increased level of pro-resolving marker IL10 at six months after DVT, but not at earlier timepoints, is associated with PTS, supporting the negative role of delayed resolution in patients [68]. After onset of PTS, patients still have increased inflammatory markers and their leukocytes express more pro-inflammatory factors than leukocytes in unaffected patients [74][75][76]. Reasons why some patients have persistent inflammation and delayed resolution are unclear.…”

Section: Leukocyte Extravasationmentioning

confidence: 92%

How to optimize the prevention of post-thrombotic syndrome: recent advances

Iding¹,

Cate‐Hoek²

2022

Polish Archives of Internal Medicine

Self Cite

View full text Add to dashboard Cite

Post-thrombotic syndrome (PTS) is the most frequent complication of deep vein thrombosis, and it can be detrimental to the quality of life of affected patients. Once affected by this chronic condition, treatment options are very limited, so preventive therapies are paramount.Currently, the prevention of PTS is hampered by the lack of unequivocally effective therapies.However, increased pathogenic insight acquired in recent years, including the central role of residual venous obstruction, could lead to better application of existing therapies and identification of novel therapeutic targets. Plausible therapeutic agents include flavonoids and statins, while promising future agents include those that target leukocyte-endothelial interaction. Moreover, differences in PTS risk were found to be partly explained by a tendency of patients to form clots which are less susceptible to lysis. Finally, identifying patients that are expected to benefit most from certain therapies is equally valuable for the success of future preventive strategies. This requires exploration of better risk stratification through machine learning techniques.

show abstract

Leukocyte gene expression in post-thrombotic syndrome

Cited by 2 publications

References 8 publications

Evaluation of expression of genes associated with post-thrombotic syndrome

Evaluation of expression of genes associated with post-thrombotic syndrome

How to optimize the prevention of post-thrombotic syndrome: recent advances

Contact Info

Product

Resources

About